Real‐World Data of Second‐Line Amrubicin Monotherapy in Patients With Extensive‐Stage Small Cell Lung Cancer Who Received First‐Line Chemoimmunotherapy or Chemotherapy: A Multicenter Retrospective Study
Cancer Medicine · 2026-05 · 15 (5)
DOI: 10.1002/cam4.71982 ↗At a glance
Multizentrische Studie in Cancer Medicine, published online on 2026-05-22. Written by Kei Sonehara and 16 co-authors. Institution: First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan. Major MEDLINE topics: Anthracyclines, Antineoplastic Agents, Lung Neoplasms, Small Cell Lung Carcinoma. Cited 1 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Topics: Onkologische Pflege
Abstract (original language)
Background
Chemoimmunotherapy is widely used as the first‐line treatment for extensive‐stage small cell lung cancer (ES‐SCLC), but treatment options for second‐line have not changed. Amrubicin monotherapy is used as the standard treatment for relapsed SCLC, but since chemoimmunotherapy became an additional indication for ES‐SCLC, the efficacy and safety of second‐line amrubicin have not been sufficiently investigated.
Methods
We enrolled a total of 131 relapsed SCLC patients who received second‐line amrubicin at eleven institutions in Japan between August 2019 and June 2023. We retrospectively examined the efficacy and safety of second‐line amrubicin monotherapy.
Results
Twenty‐five (19.1%) and 106 patients (80.9%) had sensitive and refractory relapse, respectively. 51 (38.9%) and 80 (61.1%) patients received first‐line chemoimmunotherapy and first‐line chemotherapy, respectively. The median progression‐free survival (PFS) and overall survival (OS) were 3.6 months (95% confidence interval [CI], 3.1–4.1 months) and 7.9 months (95% CI, 6.7–9.1 months), respectively. The median PFS and OS were significantly longer in the sensitive group compared with the refractory group (PFS: 6.4 vs. 3.5 months, p = 0.008, OS: 9.4 vs. 6.4 months, p = 0.021, respectively). Treatment‐related adverse events were as follows: Grade 4 neutropenia in 51 patients (38.9%), grade 3 or higher febrile neutropenia in 18 patients (13.7%), and all grade interstitial lung disease in 13 patients (9.9%). Treatment‐related death was 1 patient (0.8%).
Conclusion
Second‐line amrubicin monotherapy for relapsed SCLC may be useful and well‐tolerated as a treatment option after first‐line chemoimmunotherapy or chemotherapy.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
- Department of Respiratory Medicine, Yamanashi Prefectural Central Hospital, Kofu, Japan.
- Department of Respiratory Medicine, Nagano Municipal Hospital, Nagano, Japan.
- Department of Respiratory Medicine, National Hospital Organization Shinshu Ueda Medical Center, Ueda, Japan.
- Department of Respiratory Medicine, Nagano Red Cross Hospital, Nagano, Japan.
- Department of Respiratory Medicine, Minaminagano Medical Center, Shinonoi General Hospital, Nagano, Japan.
ORCID profiles: Kei Sonehara, Toshiharu Tsutsui, Kazunari Tateishi
Cite
APA
Sonehara, K., Tsutsui, T., Nozawa, S., Agatsuma, T., Yamamoto, M., Matsuo, A., Nakanishi, M., Chiaki, T., Kato, A., Miyahara, T., Hachiya, T., Kanda, S., Hirabayashi, T., Yanagisawa, K., Araki, T., Tateishi, K., & Hanaoka, M. (2026). Real‐World Data of Second‐Line Amrubicin Monotherapy in Patients With Extensive‐Stage Small Cell Lung Cancer Who Received First‐Line Chemoimmunotherapy or Chemotherapy: A Multicenter Retrospective Study. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71982
Vancouver
Sonehara K, Tsutsui T, Nozawa S, Agatsuma T, Yamamoto M, Matsuo A, et al. Real‐World Data of Second‐Line Amrubicin Monotherapy in Patients With Extensive‐Stage Small Cell Lung Cancer Who Received First‐Line Chemoimmunotherapy or Chemotherapy: A Multicenter Retrospective Study. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71982
BibTeX
@article{Sonehara2026,
author = {Sonehara, Kei and Tsutsui, Toshiharu and Nozawa, Shuhei and Agatsuma, Toshihiko and Yamamoto, Manabu and Matsuo, Akemi and Nakanishi, Masanori and Chiaki, Tomoshige and Kato, Akane and Miyahara, Takashige and Hachiya, Tsutomu and Kanda, Shintaro and Hirabayashi, Taro and Yanagisawa, Katsuya and Araki, Taisuke and Tateishi, Kazunari and Hanaoka, Masayuki},
title = {Real‐World Data of Second‐Line Amrubicin Monotherapy in Patients With Extensive‐Stage Small Cell Lung Cancer Who Received First‐Line Chemoimmunotherapy or Chemotherapy: A Multicenter Retrospective Study},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {5},
doi = {10.1002/cam4.71982}
}
EUVIMED